About Galvanize

Galvanize is a biomedical platform company operating at the convergence of engineering, biology, and healthcare delivery, aiming to deliver life-changing solutions to patients and their doctors.

We create Pulsed Electric Field technologies capable of targeting cells involved in disease processes, in ways unparalleled to other devices or drugs.

We study our technologies in well designed clinical trials to ensure safety and efficacy.

We partner with doctors and healthcare systems so that patients can access our therapies.

We are dedicated to operating with integrity and in full compliance with applicable health care laws and regulations. Concerns may be reported anonymously through our hotline at 1-833-214-7236, emailed to reports@lighthouse-services.com/galvantizetx.com with Galvanize in the subject line, or submitted online at www.lighthouse-services.com/galvanizetx.
 
Our California Compliance Declaration is available in accordance with California Health and Safety Code Section 119402.
Learn more about the Galvanize science and technology platform

Galvanize Leadership

Jonathan Waldstreicher, MD

Founder

BIO
Kevin Taylor
Chief Operating Officer
BIO
Bill Krimsky, MD
Chief Medical Officer
BIO
Name TK
Chief Financial Officer
BIO

Doug Godshall

Chairman and CEO

Steve Anheier

Chief Financial Officer

Kevin Taylor

Chief Operating Officer

Deb Sheffield

Chief Regulatory Officer

William S. Krimsky, MD, FCCP, DAABIP

Chief Medical Officer

Gabe McHugh

Chief Commercial Officer

Board of Directors

Doug Godshall

Chairman and CEO, Galvanize

Seth Harrison, MD

Founder and Managing Partner, ATP

Antoine Papiernik

Chairman & Managing Partner, Sofinnova Partners

Zack Scott, MD

General Partner, Norwest Venture Partners

David Lewis

Managing Partner, Gilmartin Capital

Laura Francis

CEO and Board Member of SI-BONE, Inc.

Investors

Galvanize was created and incubated by ATP (Apple Tree Partners).

Other investors in Galvanize include Intuitive Surgical, Gilmartin Capital, and T. Rowe Price; Sofinnova Partners, Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors and Longaeva.

Doug Godshall

Chairman and CEO, Galvanize

Doug Godshall was appointed Chief Executive Officer and Chairman of Galvanize in 2025. He served in his prior role as President and CEO of Shockwave Medical until its sale to Johnson & Johnson in 2024 for $13.1B. He is also the former CEO and Director of HeartWare, which was acquired by Medtronic in 2016 for $1.1B. Prior to HeartWare, Doug held executive and leadership positions at Boston Scientific. Doug also serves on the Board of Saluda Medical and is Chairman of the Medical Device Manufacturers of America (MDMA). He earned an MBA from Northeastern University and a BA in Economics from Lafayette College.

Steve Anheier

Chief Financial Officer

Steve is Chief Financial Officer at Galvanize. He brings a proven history of driving growth in revenue and profitability. Most recently, Steve was CFO of Vocera Communications, a publicly traded healthcare IT company focused on clinical communication and collaboration, which was acquired by Stryker Corporation for $3.1 billion. Steve was internally promoted into the CFO position at Vocera from his role as Vice President of Finance & Accounting. Prior to Vocera, Steve served in various roles of increasing responsibility for Accuray Incorporated in Strategic Finance and Investor Relations. He started his career at KPMG where he received his CPA and holds a bachelor’s degree in accounting from California Polytechnic State University San Luis Obispo.

Kevin Taylor

Chief Operating Officer
Kevin brings to Galvanize nearly three decades of medical device development, operational experience, and industry leadership. His device development experience spans a range of applications, including joint replacement, cardiovascular intervention, ear nose and throat therapies, and therapeutic energy delivery systems. Kevin also has extensive operational experience in pre-commercial and commercial organizations and has held key management positions in companies including Gala Therapeutics, ReCor Medical, Acclarent, and Guidant (now part of Boston Scientific). Kevin earned his mechanical engineering degree at Drexel University and received his MBA degree from the University of Chicago.

Deb Sheffield

Chief Regulatory Officer

Deborah Sheffield is Chief Regulatory Officer at Galvanize. She is an experienced professional in the design and development of innovative products, with over 25 years of experience in and understanding of the global regulatory environment in the medical device field. She has successfully obtained US and International medical device approvals for clinical studies and market clearance/approvals for Class I, II and III devices in markets including US, Canada, Australia, South America, India and Europe. Her technology experience encompasses a variety of medical devices platforms, including energy-based therapies (RF, laser, ultrasound, IRE), active implantables, and IVD devices for disease states including neuro, pulmonary, GI and cardiac functions.
Deb has previously held several key leadership positions at companies including Johnson & Johnson and at several start-up companies including Northstar Neuroscience (IPO and subsequently acquired by St. Jude Medical). She holds a BS from Kettering University in Industrial Manufacturing Engineering and a MS from Oakland University in Applied Statistics. She also attended the University of Cincinnati Nursing School with a focus on clinical research.

William S. Krimksy, MD, FCCP, DAABIP

Chief Medical Officer

William Krimsky is Chief Medical Officer of Galvanize Therapeutics®. Bill has been a pioneer in the Interventional Pulmonology space for more than 20 years, carving an innovative pathway for the treatment of lung diseases. In 2015, he and Jonathan Waldstreicher co-founded Galvanize Therapeutics and co-invented the Aliya® and RheOx® technologies, continuing his focus on therapeutic intervention in the pulmonary and oncology fields. Bill earned his medical degree at the University of Pittsburgh School of Medicine and completed an internship at Mercy Hospital and a residency at Johns Hopkins University/Sinai Hospital. Following that, he was a fellow in pulmonary and critical care medicine at Dartmouth-Hitchcock Medical Center and a visiting fellow in Interventional Pulmonology at the Hospital of the University of Pennsylvania. He is the author of multiple publications.

Gabe McHugh

Chief Commercial Officer, Galvanize

Gabe is the Chief Commercial Officer of Galvanize. He is an accomplished executive leader with nearly 25 years of success in the MedTech industry. Before joining Galvanize, he served as Executive Vice President and Global Division Head at Olympus, leading the $2.2B Surgical & Interventional Solutions Division and overseeing more than 8,000 employees worldwide. He also held multiple senior leadership roles at Medtronic, Covidien, and Cardinal Health, consistently delivering strong financial performance, market-shaping innovation, and high-performing teams. Known for his strategic clarity, and commercial acumen, he brings deep expertise in scaling businesses, developing markets, and building cultures of accountability and growth. He earned an MBA from Babson College and holds a BS from Tennessee State University.

Seth Harrison, MD

Founder and Managing Partner, ATP

Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm. Seth began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Chinook Therapeutics, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision, and ViroPharma. Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention. Seth received an AB from Princeton University and an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Antoine Papiernik

Chairman & Managing Partner, Sofinnova Partners

Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine actively invests through Sofinnova’s Capital Strategy, the firm’s flagship investment strategy. Over his career, he has been an initial investor and active board member in a number of publicly listed companies including: Actelion (ultimately sold to J&J), ProQR, NovusPharma (sold to CTI), Movetis (sold to Shire), and Shockwave Medical (sold to Johnson and Johnson). Trade sale success stories of private companies include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka). He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Pharma, May Health, Highlife and Galvanize. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.

Zack Scott, MD

General Partner, Norwest Venture Partners

Dr. Zack Scott is General Partner at Norwest Venture Partners. He previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse. Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical). Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.

David Lewis

Managing Partner, Gilmartin Capital

David Lewis is the Managing Partner of Gilmartin Capital, a firm he founded in 2021. For the previous 15 years, David was the Head of Medical Device Equity Research at Morgan Stanley, where he covered more than $1.5 trillion in market capitalization and evaluated over 150 M&A and IPO events. During his tenure at Morgan Stanley, David was the top ranked US Equity analyst in Medical Supplies & Devices. Before his time at Morgan Stanley, David was a Partner at Thomas Weisel Partners. David is a key thought leader in the sector, with decades of experience advising medical device companies and boards on strategic and financial direction. David graduated from the University of Pennsylvania with honors and a focus on pre-medical studies.

Laura Francis

CEO and Board Member of SI-BONE, Inc.

Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley based high-growth medical device company. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Laura played a pivotal role in bringing the company public in October 2018 and building the operations of the business. Prior to joining SI-BONE, Laura held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny (Nasdaq: PGNY), Promega Corporation, and Bruker Corporation (Nasdaq: BRKR). Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers. Laura was a Board Member of Shockwave Medical, Inc. (Nasdaq: SWAV), where she served as Audit Committee Chair and Compensation Committee Member, prior to its acquisition by Johnson & Johnson. She received a B.B.A. from the University of Wisconsin and a M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

Steve Ricottone

Vice President, Global Market Development
Steve is vice president of Global Market Development for the airway/COPD division of Galvanize Therapeutics. In this role, he leads commercial development activities for RheOx globally. Steve is a healthcare executive with more than 15 years of successful healthcare management experience in sales, marketing, and market development, with a focus on developing markets for breakthrough technologies internationally. Steve joined Galvanize Therapeutics from Pulmonx, a global leader in interventional pulmonology that he joined at a very early stage and left post IPO (NASDAQ; LUNG) and where he was vice president of Marketing and Market Development. Previously, Steve held various sales and marketing management roles at Baxter, Zimmer, and Bayer. Steve holds a bachelor’s degree in Physiotherapy from the University of Brussels (Belgium) and a Master of Business Administration (MBA) from the Open University, Milton Keynes (UK).

Michael Iversen

Vice President, Business Development and Commercial Strategy

Michael is Vice President of Business Development and Commercial Strategy. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.

Bill Green

Senior Vice President, Sales and Marketing

Bill serves as senior vice president of Sales and Marketing for Galvanize. Bill has been a part of the Thoracic Oncology and Interventional Oncology space since 2004. He has led early commercial teams at medical device startups, such as superDimension (acquired by Covidien/Medtronic in 2012), NeuWave Medical (acquired by Johnson & Johnson in 2015), and most recently at Auris Health, where he was the vice president of Sales. Auris was acquired by Johnson & Johnson for $3.4 billion in 2019, one of the largest pre-IPO medical device company acquisitions to date. Bill has a bachelor’s degree in Business Finance from Duquesne University.

James Stambaugh

Senior Vice President, Clinical Affairs
James is senior vice president of Clinical Affairs for Galvanize. He has over 25 years of experience in medical device and pharmaceutical development, from early-stage start-ups to large, established corporations, and has been responsible for over 35 clinical trials from FIH to pivotal phase III. Prior to joining Galvanize, James was senior vice president of Clinical Affairs at Intersect ENT, where he played a central role in taking the company from inception and concept stage in 2006, through several rounds of VC financing, to an IPO in 2014. Prior to that, James served as director, of Clinical Operations for Guidant’s Vascular Intervention division (acquired by Abbott in 2006), responsible for conduct of clinical studies for embolic protection, coronary stents, and drug-eluting stents. James started his career as an analytical chemist at an ophthalmic pharmaceutical company, InSite Vision. He holds a B.S. in Chemistry from the University of California at Davis.

Jonathan Waldstreicher, MD

Founder

Jonathan is founder of Galvanize. He has worked in medical devices as an entrepreneur, investor, and clinician. Jon was previously a partner on the MedTech team at ATP, the life sciences venture capital firm where he founded Gala Therapeutics in 2015 and Galaxy Medical in 2020, both of which were merged into Galvanize in 2022. Prior to joining ATP, Jon was a director of Global Surgery R&D at Johnson & Johnson. He started at J&J as an associate director in the Corporate Office of Science & Technology. Before medical school, Jon worked in equity research at Bear Stearns. Jon received a BA from Brandeis University in economics and an MD and MBA from Tufts University School of Medicine. He completed a general surgery internship at Tufts Medical Center in Boston.